- Roche's (RHHBY.OB) MPDL3280A drug for non-small cell lung cancer (NSCLC) helped shrink tumors in 23% of the 53 patients who took part in an early stage trial.
- Among smokers, the response rate was 26% vs 10% among those who had never smoked.
- MPDL3280A is designed to fight tumors by blocking a protein called PD-L1, which stops the immune system from attacking cancer cells. Merck and Bristol-Myers Squibb are developing similar types of immunotherapy drugs.
- Roche is investigating MPDL3280A for use in other cancers as well, including melanoma skin tumors and kidney cancer, where it has demonstrated good potential in early testing.
- Oncologist Cora Sternberg said the NSCLC trial results suggest that MPDL3280A could be "a game changer."
- The results for MPDL3280A add to encouraging data for Roche's Kadcyla drug for HER2-positive breast cancer.
Roche lung-cancer treatment could be "game changer"
Sep 29 2013, 11:21 ET